Rituximab biosimilar (Pfizer)

利妥昔单抗生物类似药（辉瑞）

Report date: 2024/01/15 10:55:06

Base Information

Drug NameRituximab biosimilar (Pfizer)
Drug Alias NameRituximabum (Pfizer)利妥昔单抗-pvvr利妥昔单抗生物仿制药（辉瑞）Rituximab (Pfizer)Rituximab-pvvr +[9] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibodyBiologics > Biosimilar
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsComplement dependent cytotoxicity (CDC) effectsCD20-directed cytolytic effects +[4] 
TargetsB-lymphocyte antigen CD20
Therapy Area/IndicationsPrimary mediastinal B cell lymphomaRichter's SyndromePemphigus +[25] 
Global Approved IndicationsPemphigusMicroscopic PolyangiitisGranulomatosis with Polyangiitis +[6] 
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2019/07/23
Country/TerritoryBelgiumCanadaUnited States +[35] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesWake Forest University Health SciencesPfizer IncNational Cancer Institute +[6] 
Inactive CompaniesN/A
Active IndicationsPrimary mediastinal B cell lymphomaRichter's SyndromePemphigus +[21] 
Inactive IndicationsLymphoproliferative DisordersLymphoma, T-CellLymphoma, B-Cell, Marginal Zone +[4] 

Other Information

ATC CodeL01XC02
Related LinksWikipediaDrugBankKEGG